Cargando…
EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway
Malignant pleural effusion (MPE) is a common clinical problem in non-small cell lung carcinoma (NSCLC) patients; however, the underlying mechanisms are still largely unknown. Recent studies indicate that the frequency of the L858R mutant form of the epidermal growth factor receptor (EGFR-L858R) is h...
Autores principales: | Tsai, Meng-Feng, Chang, Tzu-Hua, Wu, Shang-Gin, Yang, Hsiao-Yin, Hsu, Yi-Chiung, Yang, Pan-Chyr, Shih, Jin-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559673/ https://www.ncbi.nlm.nih.gov/pubmed/26338423 http://dx.doi.org/10.1038/srep13574 |
Ejemplares similares
-
Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR(mut) NSCLC in diagnosis, follow-up and treatment
por: Lüke, Florian, et al.
Publicado: (2018) -
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023) -
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015) -
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017) -
The investigation of the volatile metabolites of lung cancer from the microenvironment of malignant pleural effusion
por: Chen, Ke-Cheng, et al.
Publicado: (2021)